XML 103 R50.htm IDEA: XBRL DOCUMENT
v3.19.3

Identifiable Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Amortization of intangible assets useful life |  |  | 12 years |
Amortization of intangible assets | $ 255 | $ 297 | $ 823 | $ 909
IPR&D to product rights | 15 |  | 271 |
Impairment of intangible assets excluding goodwill | 177 | $ 519 | 1,206 | $ 1,246
Methyl ER [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
IPR&D to product rights |  |  | 174 |
Lenalidomide Product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 125 |
In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | 78 |  | 539 |
Actavis [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 59 |
Actavis [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination recognized identifiable assets | 1,626 |  | 1,626 |
Actavis [Member] | In Process Research and Development [Member] | Lenalidomide Product [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill |  |  | 355 |
Actavis [Member] | Identifiable product rights [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Impairment of intangible assets excluding goodwill | 99 |  | 667 |
Rimsa [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination recognized identifiable assets | 46 |  | 46 |
AUSTEDO [Member] | In Process Research and Development [Member] |  |  |  |
Finite-Lived Intangible Assets [Line Items] |  |  |  |
Business combination recognized identifiable assets | $ 211 |  | $ 211 |

X
- Definition Finite lived intangible assets transferred from in process research and development to product rights. + References No definition available. + Details
Name: | teva_FiniteLivedIntangibleAssetsTransferredFromInProcessResearchAndDevelopmentToProductRights
Namespace Prefix: | teva_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of assets acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=teva_MethylErMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=teva_LenalidomideProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_ActavisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=teva_ProductRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_RimsaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=teva_AustedoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |